Molecular Engineered Super‐Nanodevices: Smart and Safe Delivery of Potent Drugs into Tumors
Source abstract
Abstract
A super-nanodevice engineered at molecular level integrates various desired properties in a smart and coordinated way, and can “switch on” or “turn off” certain functionalities as required. Importantly, it can break through complex physiological barriers, and then precisely ferry potent toxic triptolide into tumor cells in vivo, thus significantly maximizing the therapeutic efficacy and reducing the drug toxicity. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
2. 10.1021/nn900002m10.1021/nn900002m ↗
3. 10.1002/adma.20110014010.1002/adma.201100140 ↗
4. 10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
5. 10.1038/nbt115910.1038/nbt1159 ↗
6. 10.1038/nmat244210.1038/nmat2442 ↗
7. 10.1016/j.progpolymsci.2009.10.00810.1016/j.progpolymsci.2009.10.008 ↗
8. 10.1021/ja207150n10.1021/ja207150n ↗
9. 10.1002/adma.20110169010.1002/adma.201101690 ↗
10. 10.1016/j.addr.2006.09.00910.1016/j.addr.2006.09.009 ↗
11. 10.1038/nmat299210.1038/nmat2992 ↗
12. 10.1021/ar200010610.1021/ar2000106 ↗
13. 10.1002/adma.20100104010.1002/adma.201001040 ↗
14. 10.1021/nn201370710.1021/nn2013707 ↗
15. 10.1002/adma.20110180610.1002/adma.201101806 ↗
16. 10.1002/adma.20110406610.1002/adma.201104066 ↗
17. 10.1021/bm900682610.1021/bm9006826 ↗
18. 10.1039/b926689e10.1039/b926689e ↗
19. 10.1039/c0py00376j10.1039/c0py00376j ↗
20. 10.1016/j.jconrel.2011.08.14110.1016/j.jconrel.2011.08.141 ↗
21. 10.1039/c2sm07402h10.1039/c2sm07402h ↗
22. 10.1016/j.biomaterials.2011.08.07410.1016/j.biomaterials.2011.08.074 ↗
23. 10.1021/ma102346a10.1021/ma102346a ↗
24. 10.1016/j.biomaterials.2011.11.00910.1016/j.biomaterials.2011.11.009 ↗
25. 10.1158/0008-5472.CAN-05-109310.1158/0008-5472.CAN-05-1093 ↗
26. 10.1002/anie.20090721010.1002/anie.200907210 ↗
27. 10.1073/pnas.070049910410.1073/pnas.0700499104 ↗
28. Yang S. · Mol. Cancer Ther. · 2003 · 2 · 65
29. Lu L. H. · Clin. Exp. Investig. Hematol. · 1992 · 3 · 1
30. 10.1016/j.fitote.2011.08.01910.1016/j.fitote.2011.08.019 ↗
31. 10.1016/j.toxlet.2011.05.00310.1016/j.toxlet.2011.05.003 ↗
32. 10.1038/nnano.2007.7010.1038/nnano.2007.70 ↗
33. 10.1073/pnas.080176310510.1073/pnas.0801763105 ↗
34. Loverde S. M. · Adv. Mater. · 2012
35. 10.1021/ja953709s10.1021/ja953709s ↗
36. 10.1021/mp900090z10.1021/mp900090z ↗
37. 10.1002/adma.20110231310.1002/adma.201102313 ↗